Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04339036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CapTemY90 for Grade 2/3 NET Liver Metastases

Study acronym: CapTemY90
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 4 to 5 Eligibility criteria expanded, about 28 words · Secondary endpoints: details revised at 2 of 8 entries · Publications: details revised at 23 of 24 entries Show 3 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 2 of 8 entries
    • Publications: details revised at 23 of 24 entries
  2. Primary and study completion dates: May 1, 2026 to Jul 1, 2028v20
  3. Re-verified, no change to tracked fieldsv19
  4. Study sites: 3 to 4v18
  5. Enrollment target: 50 to 70 Study description revised · Site contacts updated at 1 of 3 sites · Study title revised · 1 morev17 Show 4 more changesShow less
    • Study description revised
    • Site contacts updated at 1 of 3 sites
    • Study title revised
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

Show 15 earlier versionsHide 15 earlier versions
  1. Primary completion date: May 1, 2025 to May 1, 2026 Site contacts updated at 1 of 3 sitesv16 Show 1 more changeShow less
    • Site contacts updated at 1 of 3 sites
  2. Study sites: 2 to 3 Collaborators shortened, about 16 wordsv15 Show 1 more changeShow less
    • Collaborators shortened, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 3 to 2 Collaborators: 2 to 3v14 Show 1 more changeShow less
    • Collaborators: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  4. Site details revised at 1 of 3 sitesv13
  5. Re-verified, no change to tracked fieldsv12
  6. Start date: Jan 31, 2022 to Oct 7, 2021v11
  7. Study sites: 1 to 3v10
  8. Site contact updatedv9
  9. Lead sponsor: University of Pennsylvania to Abramson Cancer Center at Penn Medicine Start date changed from estimate of Jan 21, 2022 to Jan 31, 2022 · Study description expanded, about 80 words · Study title shortened, about 7 words · 1 morev8 Show 4 more changesShow less
    • Start date changed from estimate of Jan 21, 2022 to Jan 31, 2022
    • Study description expanded, about 80 words
    • Study title shortened, about 7 words
    • Collaborators expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  10. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 1, 2021 to Jan 21, 2022 · Site details revisedv7 Show 2 more changesShow less
    • Start date: Sep 1, 2021 to Jan 21, 2022
    • Site details revised
  11. Start date: May 1, 2021 to Sep 1, 2021v6
  12. Start date: Dec 1, 2020 to May 1, 2021 Primary completion date: Dec 1, 2024 to May 1, 2025 · Completion date: Dec 1, 2025 to May 1, 2026v5 Show 2 more changesShow less
    • Primary completion date: Dec 1, 2024 to May 1, 2025
    • Completion date: Dec 1, 2025 to May 1, 2026
  13. Start date: Sep 1, 2020 to Dec 1, 2020 Primary completion date: Sep 1, 2024 to Dec 1, 2024 · Completion date: Sep 1, 2025 to Dec 1, 2025v4 Show 2 more changesShow less
    • Primary completion date: Sep 1, 2024 to Dec 1, 2024
    • Completion date: Sep 1, 2025 to Dec 1, 2025
  14. Start date: Jul 1, 2020 to Sep 1, 2020 Primary completion date: Jul 1, 2024 to Sep 1, 2024 · Completion date: Jul 1, 2025 to Sep 1, 2025v3 Show 2 more changesShow less
    • Primary completion date: Jul 1, 2024 to Sep 1, 2024
    • Completion date: Jul 1, 2025 to Sep 1, 2025
  15. Secondary endpoints: 7 to 8v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
Trial Details
NCT Number NCT04339036
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov